These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36314881)

  • 21. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An age-period-cohort analysis of trends in psychedelic and ecstasy use in the Australian population.
    Chan G; Sun T; Lim C; Yuen WS; Stjepanović D; Rutherford B; Hall W; Johnson B; Leung J
    Addict Behav; 2022 Apr; 127():107216. PubMed ID: 34979428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward a New Science of Psychedelic Social Psychology: The Effects of MDMA (Ecstasy) on Social Connection.
    Lyubomirsky S
    Perspect Psychol Sci; 2022 Sep; 17(5):1234-1257. PubMed ID: 35536567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.
    Jones GM; Nock MK
    Sci Rep; 2022 Feb; 12(1):2574. PubMed ID: 35173246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
    Mithoefer MC; Grob CS; Brewerton TD
    Lancet Psychiatry; 2016 May; 3(5):481-8. PubMed ID: 27067625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations between lifetime classic psychedelic use and cardiometabolic diseases.
    Simonsson O; Osika W; Carhart-Harris R; Hendricks PS
    Sci Rep; 2021 Jul; 11(1):14427. PubMed ID: 34257396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psilocybin and MDMA for the treatment of trauma-related psychopathology.
    Bird CIV; Modlin NL; Rucker JJH
    Int Rev Psychiatry; 2021 May; 33(3):229-249. PubMed ID: 34121583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.
    Sarparast A; Thomas K; Malcolm B; Stauffer CS
    Psychopharmacology (Berl); 2022 Jun; 239(6):1945-1976. PubMed ID: 35253070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.
    Fogg C; Michaels TI; de la Salle S; Jahn ZW; Williams MT
    Exp Clin Psychopharmacol; 2021 Oct; 29(5):539-554. PubMed ID: 34096755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.
    Dunlap LE; Andrews AM; Olson DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2408-2427. PubMed ID: 30001118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.
    Yang KH; Han BH; Palamar JJ
    Addict Behav; 2022 Sep; 132():107343. PubMed ID: 35525189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations between classic psychedelics and nicotine dependence in a nationally representative sample.
    Jones G; Lipson J; Nock MK
    Sci Rep; 2022 Jun; 12(1):10578. PubMed ID: 35732796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.